Loading True North Map…
Capability profile
Use paired bacterial enzymes during ex vivo machine perfusion to remove type-A antigens from donor kidneys and other blood-group-bearing tissues. Peer-reviewed studies report approximately 80% kidney A-antigen removal within two hours and no hyperacute rejection in a preclinical human-decedent transplant model, while also recording antigen regeneration and later immune-mediated signs that remain unresolved for clinical use.
Preclinical enzyme-enabled blood and organ compatibility platform
No source-supported differentiators are published yet.
Maturity fields are not published because the reviewed sources do not support them.
Reviewed Mission areas and released Defence needs
See how the documented capability connects to reviewed Mission areas and released Defence needs—and why each connection may be worth a conversation.
A portable, workflow-compatible clinical technology for urgent or remote care could be relevant to distributed support contexts; this is a derived assessment and is not a public procurement claim.
This is a reviewed public-source assessment. It is not procurement eligibility, endorsement, customer interest, or classified demand.
Evidence limits
Continue exploring
Start with the owning organization, then compare similar areas of work and follow reviewed mission and Defence need connections, sibling capabilities, technical domains, and explicitly linked Signals and Briefs. Organization-level program participation is not attributed to this capability.
Profiles that provide the strongest reviewed or discovery-led continuation.
Follow reviewed needs, mission areas, technologies, programs, domains, regions, or focused map views.
Next useful conversation
Save the capability and its sources, then verify operating performance, maturity and integration constraints directly with the organization.
